10.3 Crystal Arthropathies & Fibromyalgia: Gout, Pseudogout & Centralized Pain Syndromes
Key Takeaways
- Gout is an inflammatory crystal arthropathy caused by monosodium urate (MSU) crystal precipitation in synovial joints when serum uric acid exceeds the solubility threshold (>6.8 mg/dL); the definitive gold standard for diagnosis is arthrocentesis demonstrating needle-shaped, intracellular, strongly negatively birefringent crystals under polarized light microscopy.
- Acute gout flares are managed with early initiation (<24–36 hours) of low-dose colchicine (1.2 mg then 0.6 mg 1 hour later), high-dose NSAIDs, or systemic/intra-articular corticosteroids; serum uric acid levels may be deceptively normal during an acute attack and should not alter acute therapy.
- Urate-Lowering Therapy (ULT) with Allopurinol is indicated for patients with ≥1 subcutaneous tophi, radiographic joint damage, frequent flares (≥2/year), or CKD stage ≥3; patients of Han Chinese, Korean (with CKD3+), Thai, and African American descent must undergo HLA-B*58:01 genetic screening prior to allopurinol initiation to prevent severe cutaneous adverse reactions (SCAR/DRESS).
- Calcium Pyrophosphate Dihydrate (CPPD) crystal deposition disease (Pseudogout) predominantly affects large joints (knee >50%, wrist) and is diagnosed by rhomboid-shaped, weakly positively birefringent crystals and radiographic chondrocalcinosis; atypical or early-onset CPPD requires screening for hemochromatosis, hyperparathyroidism, and hypomagnesemia.
- Fibromyalgia is a centralized nociplastic pain disorder characterized by chronic widespread pain (≥3 months), non-restorative sleep, severe fatigue, and cognitive dysfunction with completely normal inflammatory markers and imaging; evidence-based management centers on low-impact aerobic exercise, CBT, and FDA-approved neuromodulators (duloxetine, milnacipran, pregabalin), while strictly avoiding opioids.
Last updated: August 2026
Crystal Arthropathies & Fibromyalgia: Gout, Pseudogout & Centralized Pain Syndromes
Crystal-induced arthropathies and centralized non-inflammatory pain disorders represent opposite ends of the rheumatologic spectrum—from explosive, crystal-mediated innate immune inflammation to neuroplastic central sensitization. For the Adult-Gerontology Primary Care Nurse Practitioner (AGPCNP), board mastery requires definitive synovial fluid crystal differentiation, rigorous treat-to-target urate management, genomic safety screening, and holistic multimodal management of centralized pain syndromes while avoiding harmful opioids.
1. Gout (Monosodium Urate Crystal Arthropathy)
Pathophysiology & Inflammasome Activation
Hyperuricemia is defined as a serum urate concentration exceeding $>6.8\text{ mg/dL}$, the physicochemical saturation threshold of monosodium urate in aqueous physiological solutions at $37^\circ\text{C}$. Supersaturation promotes the nucleation and deposition of needle-shaped monosodium urate (MSU) microcrystals within intra-articular synovial fluid, cartilage, and periarticular soft tissues.
+---------------------------------------------------------------------------------------------------+
| GOUT PATHOGENIC CASCADE |
| |
| Hyperuricemia (Serum Urate > 6.8 mg/dL) -> MSU Crystal Precipitation in Synovium |
| | |
| v |
| Phagocytosis of MSU Crystals by Synovial Macrophages |
| | |
| v |
| Activation of the NLRP3 INFLAMMASOME Macromolecular Complex |
| | |
| v |
| Caspase-1 Cleavage -> Massive Release of Active INTERLEUKIN-1beta (IL-1beta) |
| | |
| v |
| Rapid Endothelial Activation + Intense Neutrophil Chemotaxis & Influx into Synovial Fluid |
| | |
| v |
| EXPLOSIVE INFLAMMATORY SYNOVITIS (Severe pain, erythema, heat, swelling, periarticular edema) |
+---------------------------------------------------------------------------------------------------+
Etiological Classification of Hyperuricemia
+---------------------------------------------------------------------------------------------------+
| ETIOLOGIES OF HYPERURICEMIA IN ADULTS |
| |
| 1. RENAL UNDEREXCRETION (~ 90% of all clinical cases) |
| - Chronic Kidney Disease (CKD - reduced glomerular filtration and tubular clearance). |
| - Metabolic Syndrome, Obesity, Hypertension, Insulin Resistance. |
| - DRUG-INDUCED UNDEREXCRETION (Classic Board Pearls!): |
| * Diuretics: THIAZIDES (Hydrochlorothiazide, Chlorthalidone) and LOOP DIURETICS (Furosemide)|
| * Low-Dose Aspirin (< 2 g/day; inhibits tubular urate secretion; high-dose is uricosuric) |
| * Calcineurin Inhibitors: Cyclosporine and Tacrolimus (common post-transplant trigger) |
| * Antituberculosis Drugs: Pyrazinamide and Ethambutol |
| * Niacin (Nicotinic acid) |
| |
| 2. PURINE OVERPRODUCTION (~ 10% of clinical cases) |
| - High Cell Turnover / Myeloproliferative & Lymphoproliferative Disorders, Hemolytic Anemias.|
| - Tumor Lysis Syndrome (massive purine release during chemotherapy). |
| - Severe Exfoliative Psoriasis. |
| - High Dietary Purine Intake: Red meat, organ meats (sweetbreads, liver), shellfish/seafood. |
| - Ethanol Consumption: Beer (rich in purines + produces lactate, which competes for renal |
| urate secretion) and distilled spirits. |
| - High-Fructose Corn Syrup & Fructose-sweetened beverages (stimulates ATP degradation). |
| - Inborn Errors of Metabolism: HGPRT deficiency (Lesch-Nyhan), PRPP synthetase overactivity. |
+---------------------------------------------------------------------------------------------------+
Clinical Stages of Gout
- Asymptomatic Hyperuricemia: Elevated serum urate without clinical symptoms or tophi. Pharmacologic ULT is generally not indicated.
- Acute Gouty Arthritis: Explosive, agonizing monarticular pain reaching peak intensity within 12 to 24 hours, often waking the patient from sleep in the early morning hours (2:00–4:00 AM). The joint is warm, swollen, dusky red, and exquisitely tender (even the touch of a bedsheet is intolerable). Overlying skin often desquamates as inflammation subsides.
- Podagra: Acute involvement of the first metatarsophalangeal (1st MTP) joint (occurs in $>50%$ of initial attacks and $>80%$ of patients lifetime).
- Other common sites: Instep/midfoot, ankles, knees, wrists, and olecranon bursa.
- Intercritical Gout: Symptom-free intervals between acute flares. Crystal deposition continues silently in articular tissues if hyperuricemia remains unmanaged.
- Chronic Tophaceous Gout: Characterized by chronic destructive polyarticular arthritis and the formation of Tophi—nodular, chalky-white deposits of monosodium urate crystals surrounded by a foreign-body granulomatous reaction. Commonly located in the helix of the ear, olecranon bursa, prepatellar bursa, Achilles tendon, and digit pads.
Diagnostics: Arthrocentesis, Serology & Imaging
- Synovial Fluid Analysis (Definitive Gold Standard): Polarized light microscopy reveals needle-shaped, intracellular crystals exhibiting STRONG NEGATIVE BIREFRINGENCE (crystals appear bright yellow when aligned parallel to the slow axis of the red compensator filter, and bright blue when perpendicular).
- Serum Uric Acid during Flare: Serum uric acid levels can be deceptively NORMAL or LOW in up to 30–40% of patients during an acute attack due to interleukin-6-mediated acute phase uricosuria. A normal uric acid during an acute joint effusion does NOT rule out gout! Diagnostic baseline uric acid must be re-evaluated 2 to 4 weeks post-flare resolution.
- Plain Radiographs: In chronic tophaceous gout, radiographs show pathognomonic "punched-out" or "rat-bite" marginal bone erosions with sclerotic overhanging edges, with preservation of the joint space until end-stage disease and an absence of periarticular osteopenia.
+---------------------------------------------------------------------------------------------------+
| STEPWISE GUIDELINE-DIRECTED GOUT MANAGEMENT |
| |
| PHASE 1: ACUTE FLARE MANAGEMENT (Initiate within 24-36 hours of onset!) |
| * FIRST-LINE OPTIONS (Choose based on patient comorbidities): |
| 1. COLCHICINE: Low-dose regimen -> 1.2 mg PO at first sign of flare, followed by 0.6 mg |
| 1 hour later (Total dose: 1.8 mg over 1 hour). Do NOT repeat within 3 days. Initiate |
| within 36 hrs of flare. (Dose reduce if CKD or taking strong CYP3A4/P-gp inhibitors). |
| 2. NSAIDs: High-dose oral NSAIDs (e.g., Naproxen 500 mg BID, Indomethacin 50 mg TID, |
| Celecoxib). AVOID in CKD (eGFR < 30), active PUD, severe CHF, or anticoagulation. |
| 3. CORTICOSTEROIDS: Oral Prednisone 30-35 mg daily for 5 days, then stop/taper OR |
| Intra-articular triamcinolone injection (ideal for 1-2 accessible large joints). |
| DRUG OF CHOICE for patients with severe renal impairment (CKD), heart failure, or PUD! |
| * CRITICAL RULE: If patient is already on Urate-Lowering Therapy (Allopurinol), DO NOT STOP |
| OR ADJUST THE DOSE during an acute flare! |
| | |
| v |
| PHASE 2: CHRONIC URATE-LOWERING THERAPY (ULT) (Treat-to-Target Strategy) |
| * Indications for ULT (2020 ACR Guidelines): |
| - >= 1 Subcutaneous Tophus on clinical exam |
| - Radiographic damage attributable to gout |
| - Frequent gout flares (>= 2 flares per year) |
| - Conditional: Prior flare with CKD Stage >= 3, Serum Urate > 9 mg/dL, or Urolithiasis. |
| * TARGET SERUM URATE LEVEL: < 6.0 mg/dL (< 5.0 mg/dL if tophaceous disease is present). |
| * FIRST-LINE ULT: ALLOPURINOL (Xanthine Oxidase Inhibitor) |
| - Starting Dose: 100 mg daily (<= 50 mg daily in CKD Stage >= 3); titrate upward every 2-4 |
| weeks by 100 mg increments until target serum urate < 6.0 mg/dL is achieved. |
| - HLA-B*58:01 GENETIC SCREENING MANDATE: Screen prior to starting Allopurinol in patients |
| of Han Chinese, Korean (with CKD3+), Thai, and African American ancestry to prevent |
| life-threatening Allopurinol Hypersensitivity Syndrome / SCAR / DRESS / Stevens-Johnson! |
| * ALTERNATIVE ULTs: Febuxostat (caution in severe CVD), Probenecid (uricosuric; requires eGFR |
| > 30 mL/min, contraindicated in nephrolithiasis), Pegloticase (IV uricase for refractory gout)|
| * MANDATORY CONCOMITANT FLARE PROPHYLAXIS: When initiating or titrating ULT, co-prescribe |
| Colchicine 0.6 mg once/twice daily (or low-dose NSAID/Prednisone <=10 mg) for AT LEAST |
| 3 TO 6 MONTHS to prevent mobilization flares triggered by rapid crystal dissolution! |
+---------------------------------------------------------------------------------------------------+
2. Calcium Pyrophosphate Dihydrate (CPPD) Crystal Deposition Disease (Pseudogout)
Pathophysiology & Chondrocalcinosis
CPPD disease is characterized by the accumulation of calcium pyrophosphate dihydrate crystals within articular cartilage, fibrocartilage, and joint capsules. Precipitation within the menisci of the knee, triangular fibrocartilage complex (TFCC) of the wrist, and symphysis pubis produces Chondrocalcinosis on plain radiography.
+---------------------------------------------------------------------------------------------------+
| GOUT vs. PSEUDOGOUT (CPPD) MATRIX |
| |
| FEATURE GOUT (MSU) PSEUDOGOUT (CPPD) |
| --------------------------------------------------------------------------------------------- |
| Crystal Composition Monosodium Urate (MSU) Calcium Pyrophosphate (CPPD) |
| Crystal Morphology Needle-shaped, sharp ends Rhomboid-shaped, rectangular |
| Polarized Light Birefringence STRONG NEGATIVE (Bright Yellow WEAK POSITIVE (Bright Blue |
| when parallel to compensator) when parallel to compensator) |
| Primary Joint Predilection 1st MTP Joint (Podagra > 50%), KNEE (> 50% of cases), |
| Instep, Ankle, Heel, Olecranon Wrist (TFCC), MCP joints, Shoulder|
| Radiographic Hallmark "Punched-out" / "Rat-bite" bone CHONDROCALCINOSIS (linear |
| erosions with overhanging edges radiodensities in cartilage) |
| Associated Conditions Metabolic syndrome, CKD, Diuretics, Hemochromatosis, Hyperparathyroid,|
| Alcohol, High-purine diet Hypomagnesemia, Hypophosphatasia |
| Chronic ULT Role Allopurinol / Febuxostat effective NO ROLE FOR ULT (Allopurinol |
| to achieve urate < 6.0 mg/dL is completely ineffective!) |
+---------------------------------------------------------------------------------------------------+
Secondary Metabolic Associations: The "4 H's" of Pseudogout
In any patient diagnosed with CPPD disease at age $<60$ or with polyarticular involvement, the AGPCNP must screen for underlying secondary metabolic and endocrine disorders:
- Hemochromatosis: Screen with Serum Ferritin and Transferrin Saturation (iron overload deposits in joints; look for hook-like osteophytes on 2nd/3rd MCPs).
- Hyperparathyroidism: Screen with Serum Calcium and intact Parathyroid Hormone (PTH).
- Hypomagnesemia: Screen with Serum Magnesium (magnesium is a natural cofactor for pyrophosphatases; low levels promote CPPD crystallization).
- Hypophosphatasia: Screen with Serum Alkaline Phosphatase (low ALP).
Treatment of Acute CPPD Arthritis
- Identical to acute gout flare management: Intra-articular corticosteroid injection, oral NSAIDs, or low-dose oral colchicine.
- Chronic flare prevention: Colchicine 0.6 mg once or twice daily.
- Urate-lowering therapies (Allopurinol, Febuxostat) have NO efficacy in CPPD disease.
3. Comprehensive Synovial Fluid Differential Matrix
+---------------------------------------------------------------------------------------------------+
| SYNOVIAL FLUID ARTHROCENTESIS ANALYSIS |
| |
| PARAMETER NORMAL NON-INFLAMMATORY (OA) INFLAMMATORY (RA/Gout) SEPTIC |
| --------------------------------------------------------------------------------------------- |
| Clarity Transparent/Clear Transparent Translucent/Opaque Opaque/Turbid|
| Color Colorless/Straw Straw / Light Yellow Yellow / Cloudy Purulent/Grey|
| Viscosity High (string >5cm)High Low Very Low |
| WBC Count (/mcL)< 200 200 - 2,000 2,000 - 50,000 > 50,000* |
| PMN Percentage < 25% < 25% > 50% > 75 - 90% |
| Glucose Ratio Equal to blood Equal to blood Mild decrease (< 50%) Very Low(<25%)|
| Crystals None None MSU or CPPD present Usually None |
| Gram Stain/Cx Negative Negative Negative Positive(>75%)|
| * Note: WBC count in severe crystal-induced arthritis can occasionally exceed 50,000/mcL; |
| always send Gram stain and bacterial culture to definitively rule out concurrent sepsis! |
+---------------------------------------------------------------------------------------------------+
4. Fibromyalgia & Centralized (Nociplastic) Pain Syndromes
Pathophysiology & Central Sensitization
Fibromyalgia is a chronic disorder of centralized pain regulation characterized by Central Sensitization and nociplastic pain (pain arising from altered central nociceptive processing without active peripheral tissue damage, inflammation, or structural lesions).
- Neurochemical Abnormalities: Elevated levels of excitatory neurotransmitters (Substance P, Glutamate) in cerebrospinal fluid, combined with profound deficits in descending pain-inhibitory serotonergic and noradrenergic pathways.
- Sleep Architecture Pathology: Non-restorative sleep caused by Alpha-Wave Intrusion into Stage 3/4 non-REM slow-wave sleep, disrupting deep restorative sleep and impairing nocturnal growth hormone secretion.
- Functional Neuroimaging (fMRI): Demonstrates augmented central pain processing (hyperconnectivity of insula and default mode network; exaggerated cerebral blood flow in response to non-painful stimuli: Allodynia).
+---------------------------------------------------------------------------------------------------+
| 2016 REVISED ACR FIBROMYALGIA CRITERIA |
| |
| A patient satisfies diagnostic criteria for Fibromyalgia if ALL 3 conditions are met: |
| |
| 1. WIDESPREAD PAIN INDEX & SYMPTOM SEVERITY SCORE: |
| - Widespread Pain Index (WPI) >= 7 AND Symptom Severity Scale (SSS) score >= 5, OR |
| - WPI between 4 - 6 AND SSS score >= 9. |
| |
| 2. GENERALIZED PAIN DISTRIBUTION: |
| - Pain must be present in at least 4 of 5 anatomical regions: |
| * Left Upper Region (jaw, shoulder, arm) |
| * Right Upper Region (jaw, shoulder, arm) |
| * Left Lower Region (hip, buttock, leg) |
| * Right Lower Region (hip, buttock, leg) |
| * Axial Region (neck, upper back, lower back, chest, abdomen) |
| |
| 3. CHRONOLOGICAL PERSISTENCE: |
| - Symptoms must be present at a similar level for AT LEAST 3 MONTHS. |
| - Note: Fibromyalgia is a valid clinical diagnosis irrespective of other medical diagnoses; |
| it does NOT exclude the presence of other concurrent illnesses (e.g., OA, SLE, RA). |
+---------------------------------------------------------------------------------------------------+
Clinical Presentation & Somatic Overlap Features
- Core Symptom Tetrad:
- Chronic, diffuse, widespread musculoskeletal aching and stiffness.
- Severe, debilitating fatigue.
- Non-restorative, fragmented sleep (waking up unrefreshed regardless of sleep duration).
- Cognitive dysfunction ("Fibro Fog": impaired concentration, short-term memory loss, mental sluggishness).
- Somatic Overlap Syndromes: Irritable bowel syndrome (IBS), tension and migraine headaches, temporomandibular joint (TMJ) dysfunction, interstitial cystitis / painful bladder syndrome, vulvodynia, postural orthostatic tachycardia syndrome (POTS), and paresthesias without dermatomal distribution.
- Physical & Laboratory Hallmark: Physical exam demonstrates multiple tender points on palpation without joint swelling, synovitis, redness, or warmth. Laboratory testing (ESR, CRP, CBC, CK, ANA, RF, thyroid function) is STRICTLY NORMAL. Normal laboratory values in a patient with agonizing widespread pain and fatigue are the diagnostic hallmark of central sensitization!
Multimodal Guideline-Directed Management of Fibromyalgia
+---------------------------------------------------------------------------------------------------+
| MULTIMODAL TREATMENT FRAMEWORK FOR FIBROMYALGIA |
| |
| NON-PHARMACOLOGIC THERAPY (First-Line & Most Effective Foundation!) |
| - Graded, Low-Impact Aerobic Exercise (walking, swimming, aquatic therapy, stationary cycling). |
| * Start at very low intensity and titrate gradually to prevent post-exertional pain flares. |
| - Cognitive Behavioral Therapy (CBT) for pain catastrophizing reduction and sleep management. |
| - Patient Education regarding central sensitization, validation of symptoms, and sleep hygiene. |
| - Tai Chi, Yoga, Mindfulness-Based Stress Reduction (MBSR). |
| | |
| v (Adjunctive pharmacotherapy) |
| EVIDENCE-BASED PHARMACOTHERAPY |
| * FDA-Approved Medications: |
| 1. DULOXETINE (Cymbalta): SNRI (30-60 mg daily). Enhances descending noradrenergic and |
| serotonergic pain inhibition; highly effective for concurrent depression and anxiety. |
| 2. MILNACIPRAN (Savella): SNRI (titrated to 50 mg BID). Inhibits norepinephrine > serotonin. |
| 3. PREGABALIN (Lyrica): Alpha-2-delta calcium channel subunit ligand (150-450 mg/day divided |
| BID/TID). Decreases excitatory Substance P and glutamate release; improves sleep. |
| * Off-Label Evidence-Supported Medications: |
| 4. AMITRIPTYLINE: Tricyclic antidepressant (10-25 mg at bedtime). Enhances slow-wave deep |
| restorative sleep and reduces pain; caution anticholinergic effects in older adults. |
| 5. CYCLOBENZAPRINE: Tricyclic-like agent (5-10 mg at bedtime); improves sleep architecture. |
| |
| --------------------------------------------------------------------------------------------- |
| CONTRAINDICATED / INEFFECTIVE MEDICATIONS IN FIBROMYALGIA (BOARD MUST-KNOW!): |
| * OPIOIDS (Oxycodone, Hydrocodone, Morphine, Codeine, Tramadol): STRONGLY DISCOURAGED! |
| - Ineffective for nociplastic pain; worsen central sensitization, cause Opioid-Induced |
| Hyperalgesia (OIH), disrupt sleep architecture, and carry high addiction/overdose mortality.|
| * BENZODIAZEPINES: Ineffective; suppress slow-wave restorative sleep; cause dependence. |
| * SYSTEMIC CORTICOSTEROIDS & NSAIDs: Ineffective because fibromyalgia is NON-INFLAMMATORY! |
+---------------------------------------------------------------------------------------------------+
5. Board-Yield Summary & Clinical Pearls
+---------------------------------------------------------------------------------------------------+
| ANCC AGPCNP CLINICAL EXAM PEARLS |
| |
| - Gout Synovial Fluid: Needle-shaped, intracellular, STRONG NEGATIVE birefringence (bright |
| yellow parallel). Normal serum uric acid during acute attack does NOT exclude gout! |
| |
| - Gout Treatment: Acute flare in CKD/renal failure = Oral Prednisone or intra-articular steroid.|
| Never stop ongoing Allopurinol during an acute flare! |
| |
| - Allopurinol Safety: Perform HLA-B*58:01 allele screening in Han Chinese, Korean (with CKD3+), |
| Thai, and African American patients before initiation to prevent fatal DRESS/SCAR syndrome! |
| Always co-prescribe colchicine flare prophylaxis for 3-6 months when starting/titrating ULT. |
| |
| - Pseudogout (CPPD): Rhomboid-shaped, WEAK POSITIVE birefringence (bright blue parallel), |
| chondrocalcinosis in knees/TFCC. Screen young/atypical patients for the "4 H's": |
| Hemochromatosis, Hyperparathyroidism, Hypomagnesemia, Hypophosphatasia. Allopurinol is useless!|
| |
| - Fibromyalgia: Chronic widespread pain >=3 months + unrefreshing sleep + fatigue. Laboratory |
| markers (ESR, CRP, CK) and imaging are completely normal. 1st-line = Low-impact exercise + |
| CBT. FDA drugs = Duloxetine, Milnacipran, Pregabalin. OPIOIDS ARE ABSOLUTELY CONTRAINDICATED!|
+---------------------------------------------------------------------------------------------------+
Test Your Knowledge
A 58-year-old male of Han Chinese descent presents to the primary care clinic for management of recurrent gout. Over the past year, he has experienced four severe, debilitating flares affecting his right 1st MTP joint, right ankle, and left knee. Physical examination reveals a 1.5-cm firm, non-tender, yellowish-white nodular deposit over his right olecranon bursa and a similar nodule on the helix of his left ear. Laboratory testing reveals: serum uric acid 10.4 mg/dL, serum creatinine 1.4 mg/dL, and eGFR 56 mL/min/1.73 m². He is currently asymptomatic between flares. The AGPCNP plans to initiate urate-lowering therapy with allopurinol to achieve a target serum urate of <5.0 mg/dL. What essential clinical action must the AGPCNP take prior to writing the allopurinol prescription?
A
B
C
D
Test Your Knowledge
A 66-year-old female presents to the urgent care clinic with acute onset of severe pain, swelling, and redness in her right knee that began 18 hours ago. She denies antecedent trauma. Her medical history is notable for primary hyperparathyroidism status-post parathyroidectomy 3 years ago and hypertension. Physical exam reveals a large, tense, warm, erythematous right knee effusion with marked limitation of active flexion. Arthrocentesis yields 35 mL of cloudy yellow fluid. Synovial fluid analysis reveals a leukocyte count of 28,000/μL with 68% neutrophils, negative Gram stain, and no bacterial growth on culture. Polarized light microscopy demonstrates rhomboid-shaped crystals that exhibit weak positive birefringence. Plain radiographs of the right knee demonstrate linear punctate radiodense calcifications within the medial and lateral menisci. What is the most accurate diagnosis?
A
B
C
D
Test Your Knowledge
A 42-year-old female presents to the primary care clinic reporting a 14-month history of constant, widespread aching musculoskeletal pain affecting her neck, upper back, lower back, bilateral shoulders, and bilateral hips. She reports severe daily exhaustion and states that even after sleeping 9 hours, she awakens feeling 'like a truck ran over me.' She describes difficulty concentrating at work and frequent episodes of abdominal bloating, cramping, and alternating diarrhea and constipation. Extensive prior workups by multiple specialists have yielded normal results. On physical examination, she exhibits marked tenderness to light digital palpation over the bilateral trapezii, second rib spaces, lateral epicondyles, and greater trochanters. There is no peripheral joint erythema, warmth, effusion, synovial thickening, or muscle weakness. Laboratory evaluation reveals: normal CBC, normal comprehensive metabolic panel, ESR 8 mm/hr, CRP 1.2 mg/L, CK 72 U/L, TSH 2.1 mIU/L, and negative ANA. What is the most appropriate initial management plan?
A
B
C
D